MA49055A - Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf - Google Patents

Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf

Info

Publication number
MA49055A
MA49055A MA049055A MA49055A MA49055A MA 49055 A MA49055 A MA 49055A MA 049055 A MA049055 A MA 049055A MA 49055 A MA49055 A MA 49055A MA 49055 A MA49055 A MA 49055A
Authority
MA
Morocco
Prior art keywords
pentacyclic
modulators
merged
tnf activity
imidazoles
Prior art date
Application number
MA049055A
Other languages
English (en)
Other versions
MA49055B1 (fr
Inventor
Daniel Christopher Brookings
Haro Garcia Teresa De
Yann Foricher
Helen Tracey Horsley
Martin Clive Hutchings
James Andrew Johnson
Malcolm Maccoss
Mengyang Xuan
Zhaoning Zhu
Original Assignee
Sanofi Sa
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, UCB Biopharma SRL filed Critical Sanofi Sa
Publication of MA49055A publication Critical patent/MA49055A/fr
Publication of MA49055B1 publication Critical patent/MA49055B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA49055A 2017-04-25 2018-04-24 Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf MA49055B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (fr) 2017-04-25 2018-04-24 Dérivés d'imidazole pentacycliques fusionnés utilisés en tant que modulateurs de l'activité du tnf

Publications (2)

Publication Number Publication Date
MA49055A true MA49055A (fr) 2021-05-05
MA49055B1 MA49055B1 (fr) 2021-12-31

Family

ID=58632834

Family Applications (2)

Application Number Title Priority Date Filing Date
MA49055A MA49055B1 (fr) 2017-04-25 2018-04-24 Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
MA57699A MA57699B1 (fr) 2017-04-25 2018-08-24 Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA57699A MA57699B1 (fr) 2017-04-25 2018-08-24 Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf

Country Status (33)

Country Link
US (3) US10980814B2 (fr)
EP (2) EP3615534B1 (fr)
JP (2) JP7083358B2 (fr)
KR (1) KR102565132B1 (fr)
CN (1) CN110582495B (fr)
AR (1) AR111426A1 (fr)
AU (1) AU2018259040B2 (fr)
BR (1) BR112019020314A2 (fr)
CA (1) CA3058980A1 (fr)
CL (1) CL2019002875A1 (fr)
CO (1) CO2019012856A2 (fr)
CR (1) CR20190526A (fr)
DK (1) DK3615534T3 (fr)
EA (1) EA039049B1 (fr)
ES (2) ES2893807T3 (fr)
HR (1) HRP20211927T1 (fr)
HU (1) HUE056593T2 (fr)
IL (1) IL269890B (fr)
LT (1) LT3615534T (fr)
MA (2) MA49055B1 (fr)
MX (1) MX2019012443A (fr)
MY (1) MY197212A (fr)
PE (1) PE20200662A1 (fr)
PH (1) PH12019502182A1 (fr)
PL (2) PL3615534T3 (fr)
PT (2) PT3615534T (fr)
RS (1) RS62596B1 (fr)
SG (1) SG11201908871SA (fr)
SI (1) SI3615534T1 (fr)
TW (1) TWI801378B (fr)
UY (1) UY37700A (fr)
WO (1) WO2018197503A1 (fr)
ZA (1) ZA201906255B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892144A1 (ru) * 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
CN113227097B (zh) * 2018-10-24 2023-09-08 Ucb生物制药有限责任公司 作为tnf活性调节剂的稠合五环咪唑衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6359008B2 (ja) 2012-06-11 2018-07-18 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ−アルファ調節ベンゾイミダゾール
EA028722B1 (ru) * 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN107108672B (zh) 2014-10-03 2019-11-08 Ucb生物制药私人有限公司 稠合的五环咪唑衍生物
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Also Published As

Publication number Publication date
IL269890B (en) 2022-03-01
AU2018259040B2 (en) 2022-04-28
JP7083358B2 (ja) 2022-06-10
JP2022116233A (ja) 2022-08-09
AU2018259040A1 (en) 2019-10-31
HRP20211927T1 (hr) 2022-03-18
PE20200662A1 (es) 2020-06-11
MX2019012443A (es) 2020-01-13
ES2956555T3 (es) 2023-12-22
EP3939980A1 (fr) 2022-01-19
EP3939980B1 (fr) 2023-07-26
WO2018197503A1 (fr) 2018-11-01
PT3939980T (pt) 2023-08-07
KR102565132B1 (ko) 2023-08-08
JP2020517637A (ja) 2020-06-18
MY197212A (en) 2023-06-01
CN110582495B (zh) 2022-04-01
CN110582495A (zh) 2019-12-17
MA49055B1 (fr) 2021-12-31
ES2893807T3 (es) 2022-02-10
PL3939980T3 (pl) 2024-02-05
TW201841918A (zh) 2018-12-01
JP7299382B2 (ja) 2023-06-27
SI3615534T1 (sl) 2022-01-31
BR112019020314A2 (pt) 2020-04-28
EP3615534A1 (fr) 2020-03-04
EA201992407A1 (ru) 2020-04-06
EP3615534B1 (fr) 2021-09-15
TWI801378B (zh) 2023-05-11
LT3615534T (lt) 2021-11-25
HUE056593T2 (hu) 2022-02-28
CR20190526A (es) 2020-01-07
PL3615534T3 (pl) 2022-01-31
MA57699B1 (fr) 2023-11-30
US20230250105A1 (en) 2023-08-10
CO2019012856A2 (es) 2020-01-17
RS62596B1 (sr) 2021-12-31
EA039049B1 (ru) 2021-11-26
KR20190141200A (ko) 2019-12-23
AR111426A1 (es) 2019-07-10
CA3058980A1 (fr) 2018-11-01
NZ758198A (en) 2024-01-26
PH12019502182A1 (en) 2020-06-08
UY37700A (es) 2018-11-30
PT3615534T (pt) 2021-10-21
CL2019002875A1 (es) 2020-03-06
DK3615534T3 (da) 2021-10-18
US20200046723A1 (en) 2020-02-13
SG11201908871SA (en) 2019-10-30
ZA201906255B (en) 2021-01-27
US10980814B2 (en) 2021-04-20
US20210252012A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA49061A (fr) Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
MA40770A (fr) Dérivés d'imidazoles pentacyclic fusionnés
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
ZA201904780B (en) System for targeted application of topical agents to an isolated body part
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
DK3273942T3 (da) Mikronåleplaster til indgivelse af en aktiv bestanddel til huden
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA43864A (fr) Utilisation de dérivés de thiohydantoin substitué en tant qu'antagonistes des récepteurs d'androgènes
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
MA43251A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
MA47593A (fr) Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase
MA49017A (fr) Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
UY35747A (es) Derivados sustituidos de fenilalanina
MA51133A (fr) Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc
MA46856A (fr) Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2